Abstract
The taccalonolides are a class of structurally and mechanistically distinct microtubule-stabilizing agents isolated from Tacca chantrieri. A crucial feature of the taxane family of microtubule stabilizers is their susceptibility to cellular resistance mechanisms including overexpression of P-glycoprotein (Pgp), multidrug resistance protein 7 (MRP7), and the βIII isotype of tubulin. The ability of four taccalonolides, A, E, B, and N, to circumvent these multidrug resistance mechanisms was studied. Taccalonolides A, E, B, and N were effective in vitro against cell lines that overexpress Pgp and MRP7. In addition, taccalonolides A and E were highly active in vivo against a doxorubicin- and paclitaxel-resistant Pgp-expressing tumor, Mam17/ADR. An isogenic HeLa-derived cell line that expresses the βIII isotype of tubulin was generated to evaluate the effect of βIII-tubulin on drug sensitivity. When compared with parental HeLa cells, the βIII-tubulin-overexpressing cell line was less sensitive to paclitaxel, docetaxel, epothilone B, and vinblastine. In striking contrast, the βIII-tubulin-overexpressing cell line showed greater sensitivity to all four taccalonolides. These data cumulatively suggest that the taccalonolides have advantages over the taxanes in their ability to circumvent multiple drug resistance mechanisms. The ability of the taccalonolides to overcome clinically relevant mechanisms of drug resistance in vitro and in vivo confirms that the taccalonolides represent a valuable addition to the family of microtubule-stabilizing compounds with clinical potential.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 8881-8888 |
| Number of pages | 8 |
| Journal | Cancer Research |
| Volume | 68 |
| Issue number | 21 |
| DOIs | |
| State | Published - Nov 1 2008 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
The taccalonolides : Microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms. / Risinger, April L; Jackson, Evelyn M.; Polin, Lisa A.; Helms, Gregory L.; LeBoeuf, Desiree A.; Joe, Patrick A.; Hopper-Borge, Elizabeth; Ludueña, Richard F.; Kruh, Gary D.; Mooberry, Susan L.
In: Cancer Research, Vol. 68, No. 21, 01.11.2008, p. 8881-8888.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The taccalonolides
T2 - Microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms
AU - Risinger, April L
AU - Jackson, Evelyn M.
AU - Polin, Lisa A.
AU - Helms, Gregory L.
AU - LeBoeuf, Desiree A.
AU - Joe, Patrick A.
AU - Hopper-Borge, Elizabeth
AU - Ludueña, Richard F.
AU - Kruh, Gary D.
AU - Mooberry, Susan L
PY - 2008/11/1
Y1 - 2008/11/1
N2 - The taccalonolides are a class of structurally and mechanistically distinct microtubule-stabilizing agents isolated from Tacca chantrieri. A crucial feature of the taxane family of microtubule stabilizers is their susceptibility to cellular resistance mechanisms including overexpression of P-glycoprotein (Pgp), multidrug resistance protein 7 (MRP7), and the βIII isotype of tubulin. The ability of four taccalonolides, A, E, B, and N, to circumvent these multidrug resistance mechanisms was studied. Taccalonolides A, E, B, and N were effective in vitro against cell lines that overexpress Pgp and MRP7. In addition, taccalonolides A and E were highly active in vivo against a doxorubicin- and paclitaxel-resistant Pgp-expressing tumor, Mam17/ADR. An isogenic HeLa-derived cell line that expresses the βIII isotype of tubulin was generated to evaluate the effect of βIII-tubulin on drug sensitivity. When compared with parental HeLa cells, the βIII-tubulin-overexpressing cell line was less sensitive to paclitaxel, docetaxel, epothilone B, and vinblastine. In striking contrast, the βIII-tubulin-overexpressing cell line showed greater sensitivity to all four taccalonolides. These data cumulatively suggest that the taccalonolides have advantages over the taxanes in their ability to circumvent multiple drug resistance mechanisms. The ability of the taccalonolides to overcome clinically relevant mechanisms of drug resistance in vitro and in vivo confirms that the taccalonolides represent a valuable addition to the family of microtubule-stabilizing compounds with clinical potential.
AB - The taccalonolides are a class of structurally and mechanistically distinct microtubule-stabilizing agents isolated from Tacca chantrieri. A crucial feature of the taxane family of microtubule stabilizers is their susceptibility to cellular resistance mechanisms including overexpression of P-glycoprotein (Pgp), multidrug resistance protein 7 (MRP7), and the βIII isotype of tubulin. The ability of four taccalonolides, A, E, B, and N, to circumvent these multidrug resistance mechanisms was studied. Taccalonolides A, E, B, and N were effective in vitro against cell lines that overexpress Pgp and MRP7. In addition, taccalonolides A and E were highly active in vivo against a doxorubicin- and paclitaxel-resistant Pgp-expressing tumor, Mam17/ADR. An isogenic HeLa-derived cell line that expresses the βIII isotype of tubulin was generated to evaluate the effect of βIII-tubulin on drug sensitivity. When compared with parental HeLa cells, the βIII-tubulin-overexpressing cell line was less sensitive to paclitaxel, docetaxel, epothilone B, and vinblastine. In striking contrast, the βIII-tubulin-overexpressing cell line showed greater sensitivity to all four taccalonolides. These data cumulatively suggest that the taccalonolides have advantages over the taxanes in their ability to circumvent multiple drug resistance mechanisms. The ability of the taccalonolides to overcome clinically relevant mechanisms of drug resistance in vitro and in vivo confirms that the taccalonolides represent a valuable addition to the family of microtubule-stabilizing compounds with clinical potential.
UR - http://www.scopus.com/inward/record.url?scp=55349087539&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=55349087539&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-08-2037
DO - 10.1158/0008-5472.CAN-08-2037
M3 - Article
C2 - 18974132
AN - SCOPUS:55349087539
VL - 68
SP - 8881
EP - 8888
JO - Cancer Research
JF - Cancer Research
SN - 0008-5472
IS - 21
ER -